We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: The SK500 clinical chemistry system (Photo courtesy of Sekisui Diagnostics).
Image: The SK500 clinical chemistry system (Photo courtesy of Sekisui Diagnostics).
Sekisui Diagnostics (Lexington, MA, USA) showcased its clinical chemistry and immunoassay analyzers, including the SK500 clinical chemistry system and FastPack IP System, at the 70th Annual Scientific Meeting & Clinical Lab Expo held by the American Association for Clinical Chemistry (AACC) on July 29 – August 2, 2018 in Chicago, USA. AACC is the largest global scientific conference and tradeshow in laboratory medicine, with ~20,000 attendees and 750 exhibitors from around the world. AACC 2018 also provided Plenary Sessions featuring world-renowned scientists and scientific sessions covering a broad range of subjects at various experience levels, and focused “Brown Bag” sessions that gave attendees the opportunity to pose questions in small groups.

Sekisui Diagnostics provides diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. The company’s product lines include clinical chemistry systems and reagents, coagulation systems and reagents, point of care rapid tests and immunoassay system, enzymes and specialty biochemical.

The SK500 Clinical Chemistry System showcased by Sekisui Diagnostics at AACC 2018 is a compact and efficient instrument with a full menu of high quality reagents specifically designed and packaged for the system, including the addition of a drugs of abuse testing menu. Sekisui Diagnostics also showcased the FastPack IP System, a fully automated quantitative immunoassay analyzer which uses sophisticated chemiluminescence technology to deliver accurate test results for commonly ordered tests in 12 minutes or less with a push of a button.

Also featured at the event was the company’s recently launched Silaris Influenza A&B Test which utilizes an affordable, polymerase chain reaction (PCR) testing platform specifically for point of care infectious disease diagnosis. It offers the simplicity, convenience and procedural familiarity of traditional visual read rapid tests, while providing the superior sensitivity and specificity of laboratory-based PCR testing.

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Silver Member
CEA Assay
Carcinoembryonic Antigen Assay
New
Epstein-Barr Virus Assay
Panther Fusion EBV Quant Assay

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.